Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.

Ingmar Wolff(Universitätsmedizin Greifswald), Cristiana Sessa(Institute of Oncology Research), Franco Cavalli(Institute of Social and Preventive Medicine), Jos H. Beijnen(The Netherlands Cancer Institute), K Bench, Y. Groot, J. de Jong, Olaf van Tellingen(Dutch Cancer Society), J. Wanders(Eisai (United Kingdom)), U. Bruntsch

PubMed

October 1, 1996

Cited by 16

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

|Cell|1994|2.3k

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

|Annals of Oncology|2015|1.4k

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

|Annals of Oncology|2019|1.2k

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2013|1.1k

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

|The Lancet|2011|1.1k